Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a prokinetic from the benzamide group, a dopamine antagonist and similar to metoclopramide (Humax 2008). It is used IV, IM and orally every 8 to 12 hours to prevent nausea and vomiting associated with medical and surgical procedures, and cancer therapies
Since the last update we have not found published data on its excretion in breastmilk.
The scarcity of known pharmacokinetic data does not allow to predict the magnitude of its possible excretion in breast milk.
Due to its chemical similarity to metoclopramide, its excretion in breastmilk could be minimal.
Due to its inhibitory effect on dopamine (DrugBank), milk production could increase due to an increase in prolactin. (Minapharm 2014, Humax 2008)
A product with very few bibliographical references and sold in very few countries.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.